Physician profile
Mark S Co
NPI 1124316005
$4,943.46
in general payments reported to CMS, 2019-2025
24 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $402 · 2021: $485 · 2022: $1,662 · 2023: $132 · 2024: $89.55 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $1,771.87 | 2019-2022 | |
| Treace Medical Concepts, INC. | $1,553.97 | 2022-2023 | |
| Zimmer Biomet Holdings, INC. | $257.97 | 2019-2021 | |
| Stryker Corporation | $243.56 | 2019-2025 | Ortholoc 3di, Sidekick |
| Bioventus LLC | $155.21 | 2019-2023 | Exogen Ultrasound Bone Healing System |
| Crossroads Extremity Systems, LLC | $151.99 | 2021 | |
| Biotissue Holdings INC. | $151.34 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.37 | 2020-2025 | Jublia |
| Organogenesis INC. | $85.96 | 2020-2024 | Puraply |
| Melinta Therapeutics, LLC | $75.03 | 2019-2022 | |
| Orthofix Medical, INC. | $70.26 | 2021-2024 | Physio-Stim, Accelstim |
| Electronic Waveform Lab, INC. | $45.76 | 2020 | |
| Acell, INC. | $31.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.92 | 2022 | |
| Smith+Nephew, INC. | $24.88 | 2025 | Renasys Go V2 Home |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrosurface Incorporated | $23.00 | 2019 | |
| Amgen INC. | $22.12 | 2024 | Krystexxa |
| Curonix LLC | $21.88 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Dynasplint Systems INC. | $20.01 | 2024 | Dynasplint |
| Omeros Corporation | $19.74 | 2020 | |
| Merck Sharp & Dohme LLC | $18.67 | 2019 | |
| Horizon Therapeutics Plc | $17.07 | 2019 | |
| Paragon 28, INC. | $16.03 | 2022 | |
| Nabriva Therapeutics, Plc | $15.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Co listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.